NASDAQ · RGNX
Healthcare · Biotechnology
$7.43
Up+$0.01 (+0.13%)
Updated Oct 3, 2026, 9:57 AM
SID Score
3.4/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · RGNX
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 2, 2026
RGNX closed at $7.43 after 20 trading sessions, down 16.89% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 2, 2026 | $7.58 | $7.62 | $7.36 | $7.43 | 1.05M |
| Oct 1, 2026 | $7.52 | $7.7363 | $7.30 | $7.42 | 1.71M |
| Sep 30, 2026 | $7.49 | $7.86 | $7.35 | $7.53 | 1.79M |
| Sep 29, 2026 | $7.41 | $7.64 | $7.33 | $7.45 | 2.1M |
| Sep 28, 2026 | $7.30 | $7.495 | $7.1701 | $7.47 | 1.33M |
| Sep 25, 2026 | $7.53 | $7.675 | $7.165 | $7.40 | 1.28M |
| Sep 24, 2026 | $7.45 | $7.46 | $7.12 | $7.24 | 1.52M |
| Sep 23, 2026 | $8.13 | $8.145 | $7.40 | $7.50 | 1.11M |
| Sep 22, 2026 | $8.03 | $8.25 | $7.9041 | $8.15 | 1.2M |
| Sep 21, 2026 | $8.24 | $8.3132 | $7.76 | $7.88 | 1.12M |
| Sep 18, 2026 | $8.22 | $8.331 | $8.00 | $8.03 | 3.38M |
| Sep 17, 2026 | $8.34 | $8.56 | $8.02 | $8.215 | 1.81M |
| Sep 16, 2026 | $7.93 | $7.99 | $7.6359 | $7.98 | 1.23M |
| Sep 15, 2026 | $8.69 | $8.75 | $7.78 | $7.945 | 1.43M |
| Sep 14, 2026 | $8.58 | $8.7276 | $8.49 | $8.69 | 858.45K |
| Sep 11, 2026 | $8.69 | $8.82 | $8.39 | $8.53 | 1.03M |
| Sep 10, 2026 | $8.63 | $8.79 | $8.47 | $8.56 | 1.17M |
| Sep 9, 2026 | $8.70 | $9.025 | $8.62 | $8.73 | 1.41M |
| Sep 8, 2026 | $8.95 | $8.95 | $8.60 | $8.76 | 998.96K |
| Sep 4, 2026 | $9.09 | $9.215 | $8.86 | $8.94 | 1.07M |
The latest Smart Investors Daily articles mentioning RGNX.
Company
Market Activity
Research & News
RGNX research
Company profile and research snapshot.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 25, 2026 | Baird | Outperform | — |
| Aug 25, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 10, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 7, 2026 | Barclays | Equal-Weight | — |
| Jun 24, 2026 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
SeekingAlpha · Sep 29, 2026
uniQure's BLA for AMT-130 is anchored on robust 36-month data, with the FDA signaling willingness to review. Click to read more about the Buy rating for QURE.
Yahoo · Sep 25, 2026
Investing.com -- Regenxbio Inc (NASDAQ:RGNX) shares rose 4.8% in premarket trading Friday after the company presented positive three-year durability data for surabgene lomparvovec in diabetic retinopathy at the Retina Society Annual Scientific Meeting.
Benzinga · Sep 25, 2026
Majority of Dose Level 3 participants with NPDR demonstrated a > 2-step DRSS improvement at 3 years post-one-time, in-office sura-vec gene therapy treatment, with no vision-threatening events and no additional
Yahoo · Sep 24, 2026
REGENXBIO Inc. (Nasdaq: RGNX) today announced positive long-term follow-up data from the Phase II ALTITUDE® study of investigational surabgenelomparvovec (sura-vec, ABBV-RGX-314) in diabetic retinopathy (DR) using suprachoroidal delivery. These new data were presented at the Retina Society 59th Annual Scientific Meeting in Los Angeles.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning RGNX.
